Welcome to our dedicated page for TREVENA news (Ticker: TRVN), a resource for investors and traders seeking the latest updates and insights on TREVENA stock.
Trevena, Inc. (Nasdaq: TRVN) is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies targeting G protein-coupled receptors (GPCRs). The company's mission is to improve patient outcomes and reduce healthcare costs through novel therapies. Trevena's pipeline includes four key drug candidates:
- TRV130 (OLINVYK®): An FDA-designated breakthrough therapy for the intravenous treatment of acute moderate to severe pain, currently in Phase 3 testing. Recently, OLINVYK's effectiveness was assessed in the VOLITION study, showing promising results in terms of respiratory, gastrointestinal, and cognitive function outcomes in postoperative settings.
- TRV027: Evaluated in a Phase 2b study for treating acute heart failure, this candidate aims to address unmet needs in cardiovascular treatment.
- TRV734: Completed Phase 1 testing for the oral treatment of acute and chronic pain, TRV734 seeks to provide a non-opioid alternative for pain management.
- TRV250: In preclinical development for migraine treatment, focusing on innovative solutions for CNS disorders.
Trevena's pipeline is based on Nobel Prize-winning research, emphasizing its commitment to pioneering medical advancements. The company has collaborations with prominent institutions like Wake Forest Baptist Health and the Cleveland Clinic, ensuring rigorous evaluation and development of its therapies. Trevena is also exploring TRV045 for diabetic neuropathic pain and epilepsy, showcasing the potential impact beyond pain management.
Financially, Trevena has shown resilience, recently reporting a net loss reduction and strengthening its balance sheet with significant capital injections. The company continues to focus on strategic partnerships and innovative research to maintain its competitive edge in the biopharmaceutical industry.
For more information, please visit www.Trevena.com.
Trevena, Inc. (Nasdaq: TRVN) recently announced initial topline data from two real-world studies, VOLITION and ARTEMIS, focusing on their opioid, OLINVYK. In VOLITION, 52.2% of OLINVYK patients were GI complete responders, with over 90% feeling 'alert and calm' post-surgery. Meanwhile, ARTEMIS revealed a 1.6-day reduction in hospital stay (approximately 27%) compared to other IV opioids. The studies involved 203 patients in VOLITION and utilized EMR data from 96 OLINVYK and 457 matched patients in ARTEMIS. Initial results reflect positively on OLINVYK's efficacy in managing postoperative pain, though full respiratory outcome data is expected mid-2023.
Trevena Inc. (Nasdaq: TRVN) announced initial topline data from the OLINVYK studies, VOLITION and ARTEMIS, demonstrating positive gastrointestinal (GI) and cognitive outcomes. In the VOLITION study of 203 patients, the GI complete response rate was 52.2%, surpassing previous Phase 3 data. ARTEMIS indicated a statistically significant 1.6-day reduction in average hospital stay compared to other IV opioids. The company has $38.3 million in cash as of year-end 2022, sufficient to fund operations into Q4 2023. Additionally, two proof-of-concept studies for TRV045, a potential treatment for CNS disorders, are underway, with top-line data expected later this year.
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company, will release its fourth quarter and full year 2022 financial results on March 30, 2023, before market open. A conference call and webcast will follow at 8:00 a.m. ET, featuring executives including Carrie Bourdow, CEO, and Barry Shin, CFO. Trevena, known for OLINVYK (oliceridine) injection for acute pain management, is also exploring innovative therapies for CNS disorders with investigational drugs like TRV045 for neuropathic pain, TRV250 for migraines, and TRV734 for opioid use disorder. The webcast will be accessible on the company's website.
FAQ
What is the current stock price of TREVENA (TRVN)?
What is the market cap of TREVENA (TRVN)?
What is Trevena, Inc.?
What is OLINVYK®?
What recent developments has Trevena announced?
What is TRV045?
How is Trevena's financial performance?
What types of products does Trevena develop?
Are Trevena's products FDA approved?
What partnerships does Trevena have?
Where can I find more information about Trevena’s research?
What are the primary focus areas of Trevena's research?
